Jim Cramer on Doximity (DOCS): “I Cannot Get Behind That”

We recently published a list of Jim Cramer Discussed These 9 Stocks Recently. In this article, we are going to take a look at where Doximity, Inc. (NYSE:DOCS) stands against other stocks that Jim Cramer discussed recently.

Noting that the stock tanked after earnings on weak guidance, a caller asked for Cramer’s opinion of Doximity, Inc. (NYSE:DOCS), and he replied:

“That was a bad miss. That was a bad miss, and that’s a high-growth company that had just been building up ahead of steam, and I cannot recommend that company because that was an unfathomable miss, frankly. And I feel very badly about saying that, but I was quite surprised. I cannot get behind that.”

A pathologist and a laboratory assistant in a laboratory researching medical news and data.

Doximity, Inc. (NYSE:DOCS) runs a digital platform designed for medical professionals and offers tools that support virtual care, career management, medical collaboration, and access to current research and news. The company also helps simplify administrative tasks and communication within the healthcare field. ClearBridge Investments stated the following regarding Doximity, Inc. (NYSE:DOCS) in its Q4 2024 investor letter:

“Doximity, Inc. (NYSE:DOCS), which offers a cloud-based collaboration platform for medical professionals that supports patient care and telehealth, was our top-performing holding in the sector. Shares rallied on a beat and raise quarter, with the company citing strong advertising revenue growth with impressive EBITDA flow through. Doximity has a history of consistent execution and, while it stumbled last year in effectively communicating realistic guidance and outlooks, it appears that management has regained investors’ trust through several quarters of solid execution.”

Overall, DOCS ranks 6th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of DOCS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DOCS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.